Stock dilution

Terra Tech Corp. Entered into an Agreement to Monetize its Investment in Hydrofarm Holdings Group, Inc., Resulting in Gross Proceeds in Excess of $40 Million

Tuesday, June 15, 2021 - 1:00pm

SANTA ANA, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Terra Tech Corp. (OTCQX:TRTC) ("Terra Tech" or the "Company") today announced that the Company entered into an agreement to monetize its investment in Hydrofarm Holdings Group, Inc., resulting in gross proceeds in excess of $40 million.

Key Points: 
  • SANTA ANA, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Terra Tech Corp. (OTCQX:TRTC) ("Terra Tech" or the "Company") today announced that the Company entered into an agreement to monetize its investment in Hydrofarm Holdings Group, Inc., resulting in gross proceeds in excess of $40 million.
  • With the expected sale of our investment in Hydrofarm, we will have added approximately $41 million to our balance sheet in just the last month, without dilution.
  • Forward-looking statements included in this release are based on information available to Terra Tech as of the date of this release.
  • Terra Tech undertakes no obligation to update such forward-looking statements to reflect events or circumstances after the date of this release.

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution

Monday, June 14, 2021 - 9:01pm

Total consideration to be paid to Xencor by INmune is $18.3 million, comprised of $15 million of cash and $3.3 million of INMB shares at a price of $17.14 resulting in the issuance of 192,533 shares.

Key Points: 
  • Total consideration to be paid to Xencor by INmune is $18.3 million, comprised of $15 million of cash and $3.3 million of INMB shares at a price of $17.14 resulting in the issuance of 192,533 shares.
  • Pursuant to the original 2017 in-licensing agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of INmunes fully diluted company shares for a period of seven years.
  • The retirement of the Xencor option eliminates an estimated 2.1 million shares of potential future common stock dilution upon exercise of the option.
  • Concurrent with this transaction, David Szymkowski, Ph.D., Vice President of Preclinical Operations at Xencor, stepped down from INmunes Board of Directors.

Advantagewon Oil Corp. Closes Over $1,000,000 Initial Tranche of Financing

Thursday, June 10, 2021 - 2:15pm

The Corporation intends to use the net proceeds of the Offering for working capital and general corporate purposes.

Key Points: 
  • The Corporation intends to use the net proceeds of the Offering for working capital and general corporate purposes.
  • Each Unit is comprised of one common share in the capital of the Corporation (a "Common Share") and one Common Share purchase warrant (a "Warrant").
  • AOC intends to close a second tranche of the Offering on or before June 25, 2021.
  • $50,000 of the combined debt total was settled via the issuance of 100,000 Common Shares at a price of $0.50 CDN per Common Share.

MassRoots Appoints Danny Meeks as Chairman of Its Board of Directors

Monday, June 7, 2021 - 12:11pm

MassRoots, Inc. ("MassRoots" or the "Company") (OTCPink:MSRT) is pleased to announce that it has appointed Danny Meeks, sole shareholder of Empire Services, Inc. (Empire), as the Chairman of its Board of Directors ahead of the planned closing of the Empire acquisition.

Key Points: 
  • MassRoots, Inc. ("MassRoots" or the "Company") (OTCPink:MSRT) is pleased to announce that it has appointed Danny Meeks, sole shareholder of Empire Services, Inc. (Empire), as the Chairman of its Board of Directors ahead of the planned closing of the Empire acquisition.
  • View the full release here: https://www.businesswire.com/news/home/20210607005225/en/
    Danny Meeks, Chairman of MassRoots (OTC Pink:MSRT) (Photo: Business Wire)
    MassRoots recently entered into a Letter of Intent to acquire Empire, which is expected to result in MassRoots generating significant revenues and positive cashflows from operations.
  • As Chairman of MassRoots, I believe it is my responsibility to deliver consistent revenue growth, acquire profitable businesses to expand our sources of revenue, and minimize dilution to our more than 30,000 loyal and supportive shareholders, stated Danny Meeks, Chairman of MassRoots.
  • Upon closing of the Empire acquisition, I believe MassRoots will have one of the most compelling stories in the small cap market.

SRHI Inc. Announces Increase in Ownership of MTV to 90.3%, Name Change to Three Valley Copper and Management Additions

Friday, June 4, 2021 - 1:45pm

On April 16, 2021, the Company announced the closing of a bought-deal financing (the Financing) to help support the operations of MTV.

Key Points: 
  • On April 16, 2021, the Company announced the closing of a bought-deal financing (the Financing) to help support the operations of MTV.
  • The Minority Shareholder did not participate resulting in the dilution of their MTV ownership from 30% to 9.7%.
  • To date, the Minority Shareholder has not contributed any capital to financially support MTV.
  • SRHI, headquartered in Toronto, Ontario, Canada is focused on growing copper production from, and further exploration of, its primary asset, MTV.

SilverCrest Metals Inc. Announces Amended Share Allocations under its Stock Incentive Plans

Friday, June 4, 2021 - 12:00pm

The SU Plan, as amended, is subject to shareholder approval which is being sought at the Company's annual general meeting to be held on Tuesday, June 15, 2021.

Key Points: 
  • The SU Plan, as amended, is subject to shareholder approval which is being sought at the Company's annual general meeting to be held on Tuesday, June 15, 2021.
  • Option Plan 5.5% (reduced from 10%) of the outstanding Common Shares from time to time for stock options granted under the Option Plan.
  • The reduced allocations of Common Shares for the SU Plan and the Option Plan are intended to reduce potential dilution to shareholders of the Company and the potential cost of these two stock incentive plans.
  • SilverCrest is the first company to successfully drill-test the historic Las Chispas Property resulting in numerous high-grade precious metal discoveries.

Guided Therapeutics Replaces Convertible Note Facility and Significantly Reduces Dilution

Thursday, June 3, 2021 - 2:05pm

The proceeds are intended to pay off an existing convertible note that matures at the end of 2021.

Key Points: 
  • The proceeds are intended to pay off an existing convertible note that matures at the end of 2021.
  • The convertible note that is being repaid included a highly dilutive discounted variable conversion mechanism based on the trading price of our common stock over the term of the note.
  • As a result, if converted, the new debenture will result in significantly less dilution than that produced by the retired note.
  • The Guided Therapeutics LuViva Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

ReelTime's Dilution Reduced by 20 Million Arising From Negotiated Settlement in Their Favor

Wednesday, May 26, 2021 - 3:56pm

SEATTLE, WA, May 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ReelTime VR/ReelTime Media (OTC:RLTR) has reduced the potential dilution by 20 million shares as a result of a successful negotiated settlement with one of its strongest supporters.

Key Points: 
  • SEATTLE, WA, May 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ReelTime VR/ReelTime Media (OTC:RLTR) has reduced the potential dilution by 20 million shares as a result of a successful negotiated settlement with one of its strongest supporters.
  • This reduces the previously obligated dilution by 20 million shares.
  • The negotiated settlement coincides with ReelTime's debt restructuring initiative to dramatically reduce the potential dilution and debt as it continues to prepare to up list to the NASDAQ Capital Markets.
  • Barry Henthorn, CEO, commented, We are incredibly pleased to have been successful in reaching an agreement that reduces the potential dilution by 20 million shares.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.

Friday, May 21, 2021 - 10:10pm

b'Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13, 2021, it acquired 10% secured convertible debentures due May 13, 2022, of Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) (the "Company") in the principal amount of US$6 million and 300,000 common share purchase warrants of the Company by way of a private placement (the "Private Placement") for a purchase price of US$6 million (Cdn$7.4 million).\nThe principal amount of the convertible debentures and accrued and unpaid interest thereon is convertible into common shares of the Company at a conversion price equal to the lesser of CDN$0.93 per share, and the 5-day volume weighted average trading price of the common shares on the date of conversion.

Key Points: 
  • b'Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13, 2021, it acquired 10% secured convertible debentures due May 13, 2022, of Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) (the "Company") in the principal amount of US$6 million and 300,000 common share purchase warrants of the Company by way of a private placement (the "Private Placement") for a purchase price of US$6 million (Cdn$7.4 million).\nThe principal amount of the convertible debentures and accrued and unpaid interest thereon is convertible into common shares of the Company at a conversion price equal to the lesser of CDN$0.93 per share, and the 5-day volume weighted average trading price of the common shares on the date of conversion.
  • Each Warrant entitles the holder to purchase one common share at an exercise price of CDN$0.93 for a term of four years.\nPrior to completion of the Private Placement, Hepalink held 85,286,524 common shares and 11,466,619 common share purchase warrants of the Company, which represented 35.72% of common shares outstanding before giving effect to any outstanding warrants, and 38.67% of the outstanding common shares assuming the exercise by Hepalink of its warrants.
  • After giving effect to the Private Placement, Hepalink held 85,286,524 common shares, 11,766,619 common share purchase warrants and US$6,000,000 principal amount of convertible debentures, which represents 35.72% of the common shares outstanding before giving effect to any outstanding warrants and convertible debentures, and 40.62% of the outstanding common shares assuming the exercise by Hepalink of its warrants and the conversion of the principal amount of the convertible debentures at a price of CDN$0.93 per share.\nThe convertible debentures and warrants were acquired for investment purposes.
  • In the future, Hepalink or any of its joint actors may, subject to applicable law, acquire or dispose of securities of the Company depending upon a number of factors, including, but not limited to, general market and economic conditions and other available investment opportunities.\nFor further information or to obtain a copy of the early warning report, please contact Bu Haihua at 86-755-2698 0311.\nShenzhen Hepalink Pharmaceutical Group Co., Ltd.\n'

AMD Announces $4 Billion Share Repurchase Program

Wednesday, May 19, 2021 - 5:21pm

b'SANTA CLARA, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) today announced that its Board of Directors approved a new share repurchase program.

Key Points: 
  • b'SANTA CLARA, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) today announced that its Board of Directors approved a new share repurchase program.
  • Under this program, the company intends to repurchase up to $4 billion of outstanding AMD common stock.
  • \xe2\x80\x9cOur strong financial results and growing cash generation enable us to invest in the business and begin returning capital to our shareholders.\xe2\x80\x9d\nUnder this program, which is designed to return value to AMD stockholders, offset dilution from stock issuances, and reduce share count over time, the company will repurchase stock in the open market.
  • AMD employees around the world are focused on building great products that push the boundaries of what is possible.